Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
Validation Efforts Stalled Again
Executive Summary
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.